Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Eupraxia Pharmaceuticals ( (TSE:EPRX) ) just unveiled an update.
On May 1, 2026, Eupraxia Pharmaceuticals announced the appointment of Dr. Jeymi Tambiah as Chief Medical Officer and the retirement of outgoing CMO Dr. Mark Kowalski, who will remain as a senior consultant during the transition. The leadership change brings a seasoned cardiothoracic surgeon and biopharma executive with more than 18 years of clinical development, regulatory and commercialization experience to support Eupraxia’s late-stage pipeline.
The company highlighted Dr. Tambiah’s track record in advancing immunology programs through late-stage clinical and regulatory milestones, positioning him to guide the development of EP-104GI for Eosinophilic Esophagitis and to help expand Eupraxia’s gastroenterology portfolio. The move underscores the strategic importance of forthcoming data from the RESOLVE trial and other pipeline catalysts, signaling a focus on executing pivotal studies and potentially strengthening the firm’s competitive stance in targeted, extended-release therapies.
The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$14.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.
Spark’s Take on EPRX Stock
According to Spark, TipRanks’ AI Analyst, EPRX is a Neutral.
The score is held back primarily by the pre-revenue model with widening losses and rising cash burn, despite a notably improved, low-debt balance sheet. Technical indicators also reflect weak near-term momentum, and valuation signals are limited by negative earnings and lack of dividend support.
To see Spark’s full report on EPRX stock, click here.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on locally delivered, extended-release therapies targeting diseases with high unmet medical need. Leveraging its proprietary Diffusphere micro-sphere technology for controlled, hyper-local drug delivery, the company is advancing candidates in pain and inflammatory gastrointestinal disorders, with potential applications across oncology, infectious disease and other critical areas.
Its lead gastroenterology asset, EP-104GI, is in a Phase 1b/2 RESOLVE trial for Eosinophilic Esophagitis, using an injectable esophageal wall delivery approach. Eupraxia has also completed a Phase 2b SPRINGBOARD trial of EP-104IAR for knee osteoarthritis pain, which met its primary endpoint and most secondary endpoints, and is building a broader pipeline of long-acting formulations for additional inflammatory joint and oncology indications.
Average Trading Volume: 77,460
Technical Sentiment Signal: Buy
Current Market Cap: C$661M
For an in-depth examination of EPRX stock, go to TipRanks’ Overview page.